Back to News
Market Impact: 0.1
Nexalin Reports New Cognitive Improvements In Alzheimer's Analysis, Plans U.S. Pilot Study
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsTechnology & Innovation
Nexalin Technology (NXL) announced results from a secondary analysis of a randomized, sham-controlled clinical trial of its Gen-2 SYNC DIFS device in patients with mild Alzheimer’s disease. The news provides an update on trial data, but no specific efficacy, safety, or quantitative outcome details were included in the provided text.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
NXL0.00
More News
- Bending Spoons wants to revive software castoffs. Berkshire is backing the plan
- AI rapidly improving, could vastly boost U.S. GDP, Anthropic's Clark tells policymakers
- ‘How many canaries have we killed in the coal mine?’ — Wall Street debates if the latest AI bubble warnings are another head fake or the real thing
- Semiconductor market to remain solid ‘at least through next year,’ South Korea finance minister says
- Nasdaq Index: AI Selloff Deepens as Chips and CoreWeave Break
- Alphabet’s chief investment officer responds to Jefferies warning that the most likely outcome of the AI boom is massive U.S. capital destruction